Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
Context: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a novel treatment approved for type 2 diabetes mellitus to lower hyperglycemia, systolic blood pressure, and promote weight loss. Commonly reported serious adverse events include increased mycotic urogenital infections, orthostatic hyp...
Main Authors: | Stephen Melnick, Priya Rajagopalan, Theresa Lynn, Anthony Donato |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado: |
Greater Baltimore Medical Center
2018-09-01
|
Series: | Journal of Community Hospital Internal Medicine Perspectives |
Subjects: | |
Acceso en liña: | http://dx.doi.org/10.1080/20009666.2018.1527667 |
Títulos similares
-
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
por: Sarayut Lahnwong, et al.
Publicado: (2018-07-01) -
Sodium–glucose co-transporter-2 inhibitors - empagliflozin and dapagliflozin as future therapy for Alport Syndrome, literature review
por: Magdalena Kłusek, et al.
Publicado: (2024-07-01) -
Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature
por: Alexis Diaz-Ramos, et al.
Publicado: (2019-09-01) -
Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure
por: Dominik Kurczyński, et al.
Publicado: (2022-07-01) -
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
por: Annamaria Mascolo, et al.
Publicado: (2022-09-01)